Literature DB >> 29406787

The Lymphangioleiomyomatosis Lung Cell and Its Human Cell Models.

Wendy K Steagall1, Gustavo Pacheco-Rodriguez1, Thomas N Darling2, Olga Torre3, Sergio Harari3, Joel Moss1.   

Abstract

Lymphangioleiomyomatosis (LAM) is a multisystem disease of women, affecting lungs, kidneys, and lymphatics. It is caused by the proliferation of abnormal smooth muscle-like LAM cells, with mutations and loss of heterozygosity in the TSC1 or, more frequently, TSC2 genes. Isolated pulmonary LAM cells have been difficult to maintain in culture, and most studies of LAM lung cells involve mixtures of TSC2 wild-type and TSC2-null cells. A clonal population of LAM lung cells has not been established, making analysis of the cells challenging. Cell lines have been established from angiomyolipomas, a common manifestation of LAM, and from tumors from patients with TSC. Circulating LAM cells have also been isolated from blood and other body fluids. LAM cells may also be identified in clusters apparently derived from lymphatic vessels. Genetics, patterns of antigen expression, and signaling pathways have been studied in LAM lung tissue and in LAM cell models, although rarely all in the same study. We show here that LAM cells manifest differences in these characteristics, depending on the source investigated, suggesting further studies.

Entities:  

Keywords:  TSC2; loss of heterozygosity; lymphangioleiomyomatosis; tuberous sclerosis

Mesh:

Year:  2018        PMID: 29406787      PMCID: PMC6002654          DOI: 10.1165/rcmb.2017-0403TR

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  74 in total

1.  Genetic heterogeneity of circulating cells from patients with lymphangioleiomyomatosis with and without lung transplantation.

Authors:  Wendy K Steagall; Li Zhang; Xiong Cai; Gustavo Pacheco-Rodriguez; Joel Moss
Journal:  Am J Respir Crit Care Med       Date:  2015-04-01       Impact factor: 21.405

2.  Exonic mutations of TSC2/TSC1 are common but not seen in all sporadic pulmonary lymphangioleiomyomatosis.

Authors:  Kameswara Rao Badri; Ling Gao; Elizabeth Hyjek; Noa Schuger; Lucia Schuger; Wei Qin; Yvonne Chekaluk; David J Kwiatkowski; Xiaoning Zhe
Journal:  Am J Respir Crit Care Med       Date:  2013-03-15       Impact factor: 21.405

3.  Isolation of individual cellular components from lung tissues of patients with lymphangioleiomyomatosis.

Authors:  Katsutoshi Ando; Naoya Fujino; Keiko Mitani; Chiharu Ota; Yoshinori Okada; Takashi Kondo; Teruaki Mizobuchi; Masatoshi Kurihara; Kenji Suzuki; Yoshito Hoshika; Hiroki Ebana; Etsuko Kobayashi; Kazuhisa Takahashi; Hiroshi Kubo; Kuniaki Seyama
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-03-25       Impact factor: 5.464

4.  mTOR activation, lymphangiogenesis, and estrogen-mediated cell survival: the "perfect storm" of pro-metastatic factors in LAM pathogenesis.

Authors:  Jane Yu; Elizabeth Petri Henske
Journal:  Lymphat Res Biol       Date:  2010-03       Impact factor: 2.589

5.  Downregulation of estrogen and progesterone receptors in the abnormal smooth muscle cells in pulmonary lymphangioleiomyomatosis following therapy. An immunohistochemical study.

Authors:  K Matsui; K Takeda; Z X Yu; J Valencia; W D Travis; J Moss; V J Ferrans
Journal:  Am J Respir Crit Care Med       Date:  2000-03       Impact factor: 21.405

6.  Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.

Authors:  Angelo M Taveira-DaSilva; Olanda Hathaway; Mario Stylianou; Joel Moss
Journal:  Ann Intern Med       Date:  2011-06-21       Impact factor: 25.391

7.  Prevalence of uterine and adnexal involvement in pulmonary lymphangioleiomyomatosis: a clinicopathologic study of 10 patients.

Authors:  Takuo Hayashi; Toshio Kumasaka; Keiko Mitani; Yasuhisa Terao; Masao Watanabe; Takashi Oide; Yukio Nakatani; Akira Hebisawa; Ryo Konno; Kazuhisa Takahashi; Takashi Yao; Kuniaki Seyama
Journal:  Am J Surg Pathol       Date:  2011-12       Impact factor: 6.394

8.  Improvement of tuberous sclerosis complex (TSC) skin tumors during long-term treatment with oral sirolimus.

Authors:  Neera Nathan; Ji-an Wang; Shaowei Li; Edward W Cowen; Mary Haughey; Joel Moss; Thomas N Darling
Journal:  J Am Acad Dermatol       Date:  2015-09-11       Impact factor: 11.527

9.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

10.  Evidence Supporting a Lymphatic Endothelium Origin for Angiomyolipoma, a TSC2(-) Tumor Related to Lymphangioleiomyomatosis.

Authors:  Michael Yue; Gustavo Pacheco; Tao Cheng; Jefferine Li; Yitang Wang; Elizabeth P Henske; Lucia Schuger
Journal:  Am J Pathol       Date:  2016-06-08       Impact factor: 4.307

View more
  6 in total

1.  Circulating Lymphangioleiomyomatosis Tumor Cells With Loss of Heterozygosity in the TSC2 Gene Show Increased Aldehyde Dehydrogenase Activity.

Authors:  Gustavo Pacheco-Rodríguez; Wendy K Steagall; Leigh Samsel; Pradeep K Dagur; J Philip McCoy; Ilker Tunc; Mehdi Pirooznia; Ji-An Wang; Thomas N Darling; Joel Moss
Journal:  Chest       Date:  2019-04-26       Impact factor: 9.410

2.  Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis.

Authors:  Radha Mukherjee; Kiran G Vanaja; Jacob A Boyer; Sunyana Gadal; Hilla Solomon; Sarat Chandarlapaty; Andre Levchenko; Neal Rosen
Journal:  Mol Cell       Date:  2021-02-18       Impact factor: 17.970

3.  A Mixed Blood-Lymphatic Endothelial Cell Phenotype in Lymphangioleiomyomatosis and Idiopathic Pulmonary Fibrosis but Not in Kaposi's Sarcoma or Tuberous Sclerosis Complex.

Authors:  Gustavo Pacheco-Rodriguez; Connie G Glasgow; Yoshihiko Ikeda; Wendy K Steagall; Zu-Xi Yu; Katsuya Tsukada; Brent W Beasley; Bernadette R Gochuico; Gulsun Erdag; Kathryn Lurain; Michelly Sampaio De Melo; Ramya Ramaswami; Thomas N Darling; Armando Filie; Joel Moss
Journal:  Am J Respir Cell Mol Biol       Date:  2022-03       Impact factor: 6.914

4.  Diagnostic performance of VEGF-D for lymphangioleiomyomatosis: a meta-analysis.

Authors:  Min Li; Wen-Ye Zhu; Ji Wang; Xiao-Dong Yang; Wei-Min Li; Gang Wang
Journal:  J Bras Pneumol       Date:  2022-03-14       Impact factor: 2.624

5.  Bioinformatics analysis of inflammation and oncology in pulmonary lymphangioleiomyomatosis.

Authors:  Wanchun Su; Zimin Zhao; Xin Liu; Jianfeng Xin; Song Xia; Wenbin Shen
Journal:  Medicine (Baltimore)       Date:  2022-09-23       Impact factor: 1.817

6.  Pulmonary lymphangioleiomyomatosis (LAM): A literature overview and case report.

Authors:  Cung-Van Cong; Tran-Thi Tuan Anh; Tran-Thi Ly; Nguyen Minh Duc
Journal:  Radiol Case Rep       Date:  2022-03-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.